Vergleich von Nieren-Biomarkern und deren Nutzen zur Überwachung der Immunsuppression

Chronic kidney disease (CKD) is on the rise among all ethnic groups. There is also evidence that this disease negatively impacts quality of life and has significant financial implications for the healthcare system, as patients require care. Therefore, it is of utmost importance that biomedical researchers take on a more active and larger role in monitoring. While there are already guidelines for screening and monitoring anticoagulant-based medications, more joint guidelines may be needed to monitor the key immunosuppressants that patients receive after a transplant. Specialists from clinical and laboratory practice must collaborate to better prepare individuals at high risk for CKD, and a prompt referral to secondary care is essential to ensure the best prognosis. Furthermore, the benefits of biomarkers for monitoring immunosuppression after transplantation need to be made more specific.